A Randomized Study of the Safety and Efficacy of BIO-11006 in Treatment of Advanced Non-Small Cell Lung Cancer in Patients Who Are Not Candidates for Curative Surgery and/or Radiation and Who Are Receiving Pemetrexed and Carboplatin
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2019
Price : $35 *
At a glance
- Drugs BIO-11006 (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors BioMarck Pharmaceuticals
- 10 Jul 2019 Results presented in a BioMarck Pharmaceuticals media release.
- 13 Mar 2019 Planned End Date changed from 30 Jun 2019 to 30 Dec 2019.
- 13 Mar 2019 Planned primary completion date changed from 31 Jan 2019 to 30 Nov 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History